Theravance Biopharma: Failed Phase 3 Trial, Strategic Review
Theravance Biopharma began a strategic review after a failed Phase 3 trial.
NASDAQ
Theravance Biopharma, Inc.
TBPH
1 story
$884M Market cap · 2026-09-23
Investor Letters
Letters that discuss TBPH.
- Laughing Water Capital H1 2026 Q2 of 2026 ANAB $1.4BGSK $95BLFCR $244M
- Summers Value Partners Q2 2026 Letter second quarter of 2026 CCSI $657M
